A new point of friction is emerging inside the Trump administration, this time centered on Food and Drug Administration Commissioner Marty Makary, who is reportedly facing mounting pressure from President Donald Trump over the pace of action on vaping policy.
According to a report published Tuesday, Trump sharply criticized Makary over the weekend, expressing frustration that the agency has not moved more quickly to approve flavored vaping and nicotine products. Sources familiar with the situation indicated that Makary’s standing within the administration has weakened, with some describing him as being on “thin ice.”
The tension appears to stem from a broader political calculation. Trump, who pledged during his 2024 campaign to “save” vaping, has reportedly taken a particular interest in the issue’s resonance with younger voters within his base. Following a series of conversations with advisers, the president questioned why flavored vape approvals had stalled, signaling a desire for faster movement from federal regulators.
Advisers reportedly painted Makary as an obstacle to that agenda, telling the president that the commissioner had resisted efforts to advance approvals for flavored products. At the center of the dispute is Makary’s earlier decision to reject authorization for menthol, mango, and blueberry vape products produced by a Los Angeles-based manufacturer. That move aligned with longstanding concerns within the FDA about the potential appeal of flavored nicotine products to younger users.
Makary’s hesitation reflects a more cautious approach rooted in public health considerations. Sources indicated he had been wary of approving flavors that could attract children, citing the potential risks associated with increased youth vaping. While he has recently discussed the possibility of softening his stance in conversations with Trump, it remains unclear whether any meaningful policy shift is forthcoming.
The situation underscores a familiar dynamic within the administration, where policy priorities can quickly collide with regulatory caution. Trump’s push to deliver on campaign promises, particularly those tied to key voter groups, appears to be clashing with the FDA’s traditionally measured approach to health risks and product approvals.
Makary, who was nominated by Trump following his 2024 election victory and confirmed in March 2025, now finds himself navigating a politically sensitive issue that carries both electoral and public health implications. His future in the role may depend on whether he can reconcile those competing pressures.
If Makary were to be dismissed, he would join a growing list of high-profile departures from the administration, including former Attorney General Pam Bondi and former Homeland Security Secretary Kristi Noem.
The broader debate over flavored vaping products is not new. The FDA has maintained a ban on flavored cartridge-based e-cigarettes since 2020, citing concerns over youth usage. Several states, including New York and California, have also implemented their own restrictions on flavored tobacco and vape products, reflecting ongoing unease about the long-term health consequences.
As the administration weighs its next steps, the dispute highlights a deeper question about governance: how to balance political commitments with regulatory responsibility. And while the issue at hand may center on vaping, the underlying tension—between urgency and caution—echoes across policy arenas, where swift action can carry consequences that are not always easily reversed.
[READ MORE: Alberta Separatists Push Referendum Bid as Political Reality Check Looms]
